AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Byline: Stephen Pounds
Jul. 20--Losses at Nabi Biopharmaceuticals deepened in the second quarter as the company felt the full effect of losing its best-selling drug this year and deferring revenue on the sale of another drug, the company said Tuesday.
Boca Raton-based Nabi lost $21 million, or 35 cents a share, compared with a loss of almost $18 million, or 30 cents a share, for the April-through-June quarter last year. Quarterly sales were $26 million vs. $48 million. The company ended the quarter with $157 million in cash and marketable securities.
In March, Nabi lost its U.S. licensing and distribution rights for top-selling WinRho, a treatment …